Drug Profile
AVID 100
Alternative Names: AVID-100Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Formation Biologics
- Developer Forbius; National Research Council Canada
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
- Phase I/II Solid tumours
Most Recent Events
- 30 Jan 2021 Formation Biologics terminated the phase Ia/IIa trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) due to lack of efficacy (NCT03094169)
- 21 Sep 2020 Forbius has been acquired by Bristol-Myers Squibb
- 26 Oct 2019 Efficacy data from a phase Ia/IIa trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2019)